Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | MERTK | Q12866 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | GNAI2 | P04899 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448841 | 0.94 | TYRO3 (0.42) | SYKEGFRPTK2TYRO3MERTK | |
| SCHEMBL3451973 | 0.93 | CSF1R (0.44) | SYKEGFRPTK2TYRO3MERTK | |
| SCHEMBL3448901 | 0.91 | EGFR (0.41) | SYKEGFRPTK2ABL1AURKA | |
| SCHEMBL3450350 | 0.87 | PTK2 (0.45) | SYKEGFRPTK2ABL1AURKA | |
| SCHEMBL3378656 | 0.86 | PTK2 (0.37) | SYKEGFRPTK2TYRO3MERTK | |
| SCHEMBL3449213 | 0.86 | SYK (0.41) | SYKEGFRNTRK1KDR | |
| SCHEMBL3450103 | 0.86 | SYK (0.41) | SYKEGFRMERTKAXLCSNK2A1 | |
| SCHEMBL13312593 | 0.86 | SYK (0.38) | SYKEGFR | |
| SCHEMBL3449077 | 0.86 | SYK (0.39) | SYKEGFR | |
| SCHEMBL3450073 | 0.86 | EGFR (0.41) | SYKEGFRPTK2ABL1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885EGFR 2771/4885PTK2 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.